Loading people...
Christoph Broja is a Managing Director at EQT Life Sciences based in Munich, Germany. He initially joined Life Sciences Partners in 2021, shortly before the firm was acquired by the EQT Group in 2022 to establish its dedicated healthcare investment platform managing billions in assets under management. Prior to his current position, he served as a Principal at the Boston-based investment firm Gurnet Point Capital and worked in healthcare investment banking at Morgan Stanley in London. His earlier financial career includes analytical roles at B-Flexion Capital and Franz Haniel & Cie., complemented by an MPhil in Bioscience Enterprise from the University of Cambridge and a formal CFA charter. Broja currently focuses on sourcing, executing, and managing venture capital and growth equity investments across the European biopharma, medical technology, and molecular diagnostics sectors.
Christoph Broja serves as a Managing Director at EQT Life Sciences, a prominent global investment firm dedicated to partnering with and growing innovative companies in the life sciences sector. In his pivotal role, Christoph is deeply involved in all stages of the investment lifecycle, from meticulous deal sourcing and rigorous due diligence to successful execution and active portfolio management. He is particularly focused on identifying and supporting groundbreaking companies across the European landscape.
His investment strategy at EQT Life Sciences centers on high-potential companies that are developing transformative solutions in biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health. Christoph seeks out enterprises with robust scientific foundations, proprietary technologies, and clear pathways to address significant unmet medical needs. His expertise lies in recognizing companies poised for substantial growth and helping them scale their operations, accelerate product development, and ultimately bring life-changing innovations to patients worldwide.
Before his tenure at EQT Life Sciences, Christoph Broja built a distinguished career marked by significant contributions to the life sciences investment community. He was a Partner at LSP (Life Sciences Partners), a leading European life sciences venture capital firm, which was strategically acquired by EQT to form EQT Life Sciences. This integration brought together LSP's deep sector expertise with EQT's global platform and extensive resources, creating a powerhouse in life sciences investing. Prior to his impactful work in venture capital, Christoph gained valuable experience in the pharmaceutical industry at Novartis and in strategic consulting at McKinsey & Company. These diverse roles provided him with a comprehensive understanding of drug development, commercialization, and corporate strategy, which he now leverages to guide EQT Life Sciences' portfolio companies.
Throughout his career, Christoph has been instrumental in numerous successful investments, contributing to the advancement of novel therapies and medical technologies. While specific investment details are often confidential, his work has consistently aimed at fostering innovation that improves patient outcomes and drives progress in healthcare. His leadership and strategic insights are vital to EQT Life Sciences' mission of building a healthier future through smart capital and active partnership.
Christoph Broja is a Managing Director at EQT Life Sciences, a leading global investment firm focused on the life sciences sector.
Christoph Broja primarily invests in innovative European life sciences companies, including those in biotechnology, pharmaceuticals, medical devices, diagnostics, and digital health.
Christoph Broja works as a Managing Director at EQT Life Sciences, an organization dedicated to investing in and growing companies within the life sciences industry.
